MannKind Stock

MannKind EBIT

The EBIT of MannKind (MNKD) as of Aug 13, 2026 is 38.80 M USD. In the previous year, EBIT was 72.59 M USD — a change of -46.55% (lower).

EBIT

38.80 MUSD

YoY

-46.55%

Last updated:

In 2026, MannKind's EBIT was 38.80 M USD, a -46.55% increase from the 72.59 M USD EBIT recorded in the previous year.

The MannKind EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2023
8.68 base
Jan 1, 2024
72.59 base
Jan 1, 2025
38.80 base
Jan 1, 2026 (e)
-105.93 base
Jan 1, 2027 (e)
-119.32 base
Jan 1, 2028 (e)
-122.77 base
Jan 1, 2029 (e)
-139.89 base
Jan 1, 2030 (e)
-161.44 base
YEAREBIT (M USD)
2030 est -161.44
2029 est -139.89
2028 est -122.77
2027 est -119.32
2026 est -105.93
2025 38.80
2024 72.59
2023 8.68
2022 -65.14
2021 -64.35
2020 -47.99
2019 -41.99
2018 -77.80
2017 -104.30
2016 67.26
2015 -344.66
2014 -179.63
2013 -169.40
2012 -146.96
2011 -140.54
2010 -152.50
2009 -209.78
2008 -305.77
2007 -307.36
2006 -233.70
Access this data via the Eulerpool API

MannKind Revenue

MannKind Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
198.96 M USD
8.68 M USD
-11.94 M USD
Jan 1, 2024
285.50 M USD
72.59 M USD
27.59 M USD
Jan 1, 2025
348.97 M USD
38.80 M USD
5.86 M USD
Jan 1, 2026 (e)
463.02 M USD
-105.93 M USD
-4.71 M USD
Jan 1, 2027 (e)
521.57 M USD
-119.32 M USD
44.37 M USD
Jan 1, 2028 (e)
536.64 M USD
-122.77 M USD
48.52 M USD
Jan 1, 2029 (e)
611.47 M USD
-139.89 M USD
96.03 M USD
Jan 1, 2030 (e)
705.66 M USD
-161.44 M USD
142.40 M USD

MannKind Margins

MannKind stock margins

The MannKind margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MannKind. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MannKind.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
68.45 %
4.36 %
-6.00 %
Jan 1, 2024
73.17 %
25.42 %
9.66 %
Jan 1, 2025
82.47 %
11.12 %
1.68 %
Jan 1, 2026 (e)
82.47 %
-22.88 %
-1.02 %
Jan 1, 2027 (e)
82.47 %
-22.88 %
8.51 %
Jan 1, 2028 (e)
82.47 %
-22.88 %
9.04 %
Jan 1, 2029 (e)
82.47 %
-22.88 %
15.70 %
Jan 1, 2030 (e)
82.47 %
-22.88 %
20.18 %

MannKind Stock analysis

What does MannKind do? MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing MannKind's EBIT

MannKind's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of MannKind's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

MannKind's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in MannKind’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about MannKind stock

EBIT of MannKind is 38.80 M USD in 2026.

EBIT of MannKind changed from 72.59 M USD to 38.80 M USD, representing a -46.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT MannKind since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's MannKind historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — MannKind

All Key Metrics — MannKind